| Literature DB >> 30689758 |
Felix Chan1,2, Nichola Z Lax2, Caroline Marie Voss3, Blanca Irene Aldana3, Shuna Whyte1, Alistair Jenkins4, Claire Nicholson4, Sophie Nichols1, Elizabeth Tilley1, Zoe Powell1, Helle S Waagepetersen3, Ceri H Davies5, Doug M Turnbull2, Mark O Cunningham1,6.
Abstract
Approximately one-quarter of patients with mitochondrial disease experience epilepsy. Their epilepsy is often severe and resistant towards conventional antiepileptic drugs. Despite the severity of this epilepsy, there are currently no animal models available to provide a mechanistic understanding of mitochondrial epilepsy. We conducted neuropathological studies on patients with mitochondrial epilepsy and found the involvement of the astrocytic compartment. As a proof of concept, we developed a novel brain slice model of mitochondrial epilepsy by the application of an astrocytic-specific aconitase inhibitor, fluorocitrate, concomitant with mitochondrial respiratory inhibitors, rotenone and potassium cyanide. The model was robust and exhibited both face and predictive validity. We then used the model to assess the role that astrocytes play in seizure generation and demonstrated the involvement of the GABA-glutamate-glutamine cycle. Notably, glutamine appears to be an important intermediary molecule between the neuronal and astrocytic compartment in the regulation of GABAergic inhibitory tone. Finally, we found that a deficiency in glutamine synthetase is an important pathogenic process for seizure generation in both the brain slice model and the human neuropathological study. Our study describes the first model for mitochondrial epilepsy and provides a mechanistic insight into how astrocytes drive seizure generation in mitochondrial epilepsy.Entities:
Mesh:
Year: 2019 PMID: 30689758 PMCID: PMC6519661 DOI: 10.1093/brain/awy320
Source DB: PubMed Journal: Brain ISSN: 0006-8950 Impact factor: 13.501